Robert S Wallis

Summary

Publications

  1. doi request reprint Pulmonary infectious complications of tumor necrosis factor blockade
    Robert S Wallis
    Pfizer, New London, CT 06320, USA
    Infect Dis Clin North Am 24:681-92. 2010
  2. pmc Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model
    Robert S Wallis
    Specialty Care, Pfizer, Groton, Connecticut, United States of America
    PLoS ONE 8:e71116. 2013
  3. doi request reprint Tumour necrosis factor antagonists: structure, function, and tuberculosis risks
    Robert S Wallis
    PPD Inc, Washington, DC, USA
    Lancet Infect Dis 8:601-11. 2008
  4. doi request reprint Infectious complications of tumor necrosis factor blockade
    Robert S Wallis
    Pfizer, New London, Connecticut 06320, USA
    Curr Opin Infect Dis 22:403-9. 2009
  5. pmc Strain specificity of antimycobacterial immunity in whole blood culture after cure of tuberculosis
    Robert S Wallis
    Pfizer Specialty Care, New London, CT 06320, USA
    Tuberculosis (Edinb) 89:221-4. 2009
  6. doi request reprint Adalimumab treatment of life-threatening tuberculosis
    Robert S Wallis
    Pfizer, New London, Connecticut 06320, USA
    Clin Infect Dis 48:1429-32. 2009
  7. pmc Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis
    Robert S Wallis
    Pfizer, Groton New London, CT 06320, USA
    Antimicrob Agents Chemother 55:567-74. 2011
  8. pmc Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide
    Robert S Wallis
    Pfizer, Groton, Connecticut, United States of America
    PLoS ONE 7:e30479. 2012
  9. doi request reprint Tuberculosis biomarkers discovery: developments, needs, and challenges
    Robert S Wallis
    Specialty Care, Pfizer, Groton, CT, USA
    Lancet Infect Dis 13:362-72. 2013
  10. doi request reprint Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade
    Robert S Wallis
    PPD Inc, Washington, DC 20005, USA
    Arthritis Rheum 58:947-52. 2008

Collaborators

Detail Information

Publications28

  1. doi request reprint Pulmonary infectious complications of tumor necrosis factor blockade
    Robert S Wallis
    Pfizer, New London, CT 06320, USA
    Infect Dis Clin North Am 24:681-92. 2010
    ..Further research is needed to determine how best to prevent and manage their infectious complications and to determine their potential adjunctive therapeutic role in chronic infectious diseases...
  2. pmc Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model
    Robert S Wallis
    Specialty Care, Pfizer, Groton, Connecticut, United States of America
    PLoS ONE 8:e71116. 2013
    ..New drugs and regimens with the potential to transform tuberculosis treatment are presently in early stage clinical trials...
  3. doi request reprint Tumour necrosis factor antagonists: structure, function, and tuberculosis risks
    Robert S Wallis
    PPD Inc, Washington, DC, USA
    Lancet Infect Dis 8:601-11. 2008
    ..Clinical strategies for prevention and management of tuberculosis in patients treated with TNF blockers may be improved based on our evolving understanding of these differences...
  4. doi request reprint Infectious complications of tumor necrosis factor blockade
    Robert S Wallis
    Pfizer, New London, Connecticut 06320, USA
    Curr Opin Infect Dis 22:403-9. 2009
    ....
  5. pmc Strain specificity of antimycobacterial immunity in whole blood culture after cure of tuberculosis
    Robert S Wallis
    Pfizer Specialty Care, New London, CT 06320, USA
    Tuberculosis (Edinb) 89:221-4. 2009
    ..However, additional studies will be required to confirm these observations in additional patient and microbial populations that are distinct according to geography and microbial and host genetics...
  6. doi request reprint Adalimumab treatment of life-threatening tuberculosis
    Robert S Wallis
    Pfizer, New London, Connecticut 06320, USA
    Clin Infect Dis 48:1429-32. 2009
    ..Clinical improvement occurred only after resumption of adalimumab treatment...
  7. pmc Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis
    Robert S Wallis
    Pfizer, Groton New London, CT 06320, USA
    Antimicrob Agents Chemother 55:567-74. 2011
    ..06 log) (P = 0.002). In conclusion, PNU-100480 was safe and well tolerated at all tested doses. Further studies in patients with tuberculosis are warranted. Biomarkers can accelerate early development of new tuberculosis treatments...
  8. pmc Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide
    Robert S Wallis
    Pfizer, Groton, Connecticut, United States of America
    PLoS ONE 7:e30479. 2012
    ..Further testing of regimens including these compounds is warranted. Measurement of whole blood bactericidal activity can accelerate the development of novel TB regimens...
  9. doi request reprint Tuberculosis biomarkers discovery: developments, needs, and challenges
    Robert S Wallis
    Specialty Care, Pfizer, Groton, CT, USA
    Lancet Infect Dis 13:362-72. 2013
    ..We review progress in tuberculosis biomarker development and efforts being made to harness resources to meet future challenges...
  10. doi request reprint Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade
    Robert S Wallis
    PPD Inc, Washington, DC 20005, USA
    Arthritis Rheum 58:947-52. 2008
    ..These 2 pathogenic mechanisms cannot otherwise be readily distinguished...
  11. doi request reprint Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice
    Robert S Wallis
    Pfizer, New London, CT, USA
    Lancet 375:1920-37. 2010
    ..Translation of scientific progress in biomarkers and diagnostics into clinical and public health programmes is possible-with political commitment, increased funding, and engagement of all stakeholders...
  12. ncbi request reprint Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma
    Robert S Wallis
    PPD, Washington, DC, USA
    J Investig Dermatol Symp Proc 12:16-21. 2007
    ..IL-10 production was equally suppressed by all three drugs, excluding excess IL-10 as a regulatory mechanism. The tuberculosis risk posed by infliximab may reflect its combined effects on TNF and IFNgamma...
  13. doi request reprint Sustainable tuberculosis drug development
    Robert S Wallis
    Clinical Research, Specialty Therapeutics, Pfizer Inc, Groton, CT 06340, USA
    Clin Infect Dis 56:106-13. 2013
    ..A global outcomes registry would confirm safety and effectiveness in both DS and DR tuberculosis, making possible the second transformation of tuberculosis treatment. We should do our utmost to see it succeed...
  14. doi request reprint Biomarkers for tuberculosis disease activity, cure, and relapse
    Robert S Wallis
    Pfizer, New London, USA
    Lancet Infect Dis 9:162-72. 2009
    ..These studies will benefit from multidisciplinary collaborations including microbiologists, immunologists, clinicians, tuberculosis control personnel, and the pharmaceutical and biotechnology industry...
  15. doi request reprint Mycobactericidal Activity of Sutezolid (PNU-100480) in Sputum (EBA) and Blood (WBA) of Patients with Pulmonary Tuberculosis
    Robert S Wallis
    Formerly Pfizer Inc, Groton, Connecticut, United States of America
    PLoS ONE 9:e94462. 2014
    ..Like linezolid, it is unaffected by mutations conferring resistance to standard TB drugs. This study of sutezolid is its first in tuberculosis patients...
  16. doi request reprint Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers
    Robert S Wallis
    Pfizer, 50 Pequot Avenue, New London, CT 06320, USA
    J Infect Dis 202:745-51. 2010
    ..Two metabolites contribute to but do not fully account for its superiority. This study examined the safety, tolerability, pharmacokinetics, and mycobactericidal activity of single ascending doses of PNU-100480...
  17. doi request reprint Biologics and infections: lessons from tumor necrosis factor blocking agents
    Robert S Wallis
    Department of Specialty Care, Pfizer, Groton, CT 06340, USA
    Infect Dis Clin North Am 25:895-910. 2011
    ..This article focuses on recent studies that inform prevention and management of infections in this susceptible patient population...
  18. ncbi request reprint Reconsidering adjuvant immunotherapy for tuberculosis
    Robert S Wallis
    PPD, Washington, DC, USA
    Clin Infect Dis 41:201-8. 2005
    ..Prolonged treatment is presently required to prevent relapse, which is thought to arise from persisting foci of semidormant infection contained within granulomas...
  19. ncbi request reprint Structural-functional relationships of TNF-alpha antagonists: next steps
    Frank J Dann
    Amgen Inc, Thousand Oaks, California 91320 1799, USA
    J Investig Dermatol Symp Proc 12:46-7. 2007
    ..The data presented in this supplement highlight the need for further research into these key areas, and illustrate our current understanding of the mode of action of TNF blockers as only the tip of the iceberg...
  20. ncbi request reprint Anti-tuberculosis treatment and infliximab
    Robert S Wallis
    Respir Med 99:1620-2. 2005
  21. ncbi request reprint A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3)
    Robert S Wallis
    The University Medicine and Dentistry of New Jersey New Jersey Medical School, Newark, USA
    J Acquir Immune Defic Syndr 32:281-6. 2003
    ..The potential role of corticosteroids as tools to examine this question will be limited by concerns regarding their toxicity; however, further studies of other agents to limit cellular activation in AIDS are warranted...
  22. ncbi request reprint A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis
    Robert S Wallis
    Department of Medicine, Case Western Reserve University, Cleveland, OH, USA
    AIDS 18:257-64. 2004
    ..This phase 1 study examined the safety, microbiology, immunology, and virology of TNF blockade using etanercept (soluble TNF receptor, Enbrel) during the initial treatment of HIV-associated tuberculosis...
  23. ncbi request reprint Granulomatous infections due to tumor necrosis factor blockade: correction
    Robert S Wallis
    Clin Infect Dis 39:1254-5. 2004
  24. ncbi request reprint Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab
    Robert S Wallis
    UMDNJ New Jersey Medical School, Newark, NJ, USA
    Semin Arthritis Rheum 34:34-8. 2005
    ..TNF is known to participate in the induction and maintenance of protective granulomas at multiple steps, and evidence supporting a differential inhibition of TNF bioactivity and signaling by the 2 drugs is discussed...
  25. ncbi request reprint Reactivation of latent granulomatous infections by infliximab
    Robert S Wallis
    University of Medicine and Dentistry New Jersey, New Jersey Medical School, Newark, New Jersey, USA
    Clin Infect Dis 41:S194-8. 2005
    ..The ability of infliximab to disrupt established granulomas may be distinct from its ability to neutralize soluble TNF. Further research to elucidate the mechanism of the antigranuloma activity of infliximab is warranted...
  26. ncbi request reprint Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity
    Oluwabunmi Y Saliu
    Department of Medicine, University of Medicine and Dentistry, New Jersey Medical School, Newark, USA
    J Infect Dis 194:486-92. 2006
    ..The risk of reactivation of latent Mycobacterium tuberculosis infection is greater with the TNF monoclonal antibody infliximab than with the soluble TNF receptor etanercept. The basis of this difference is not known...
  27. ncbi request reprint Persistence, not resistance, is the cause of loss of isoniazid effect
    Robert S Wallis
    J Infect Dis 195:1870-1; author reply 1872-3. 2007
  28. pmc Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis
    Seon Hee Cheon
    Case Western Reserve University, Cleveland, Ohio, USA
    Clin Diagn Lab Immunol 9:901-7. 2002
    ..These experiments indicate that whole blood culture may be used to measure immunity to M. tuberculosis and that further studies of repeated BCG vaccination are warranted...